Compassionate use experience with dasatinib therapy in patients after imatinib and/or nilotinib failure

被引：0
|
作者：
Gunawardena, Bettina A. [1 ]
Schlief, Sarah [1 ]
Dempke, Wolfram [1 ]
Wnterhalter, Bernd [1 ]
机构：
[1] Bristol Myers Squibb GmbH & Co KGaA, Munich, Germany
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4561.4561
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4561
引用
收藏
页码：212B / 212B
页数：1
相关论文
共 50 条
  • [31] COMPARATIVE ANALYSIS OF PULMONARY HYPERTENSION IN THE 105 CML PATIENTS TREATED WITH IMATINIB, NILOTINIB AND DASATINIB
    Minami, M.
    Miyamoto, T.
    Akashi, K.
    HAEMATOLOGICA, 2017, 102 : 728 - 728
  • [32] NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib
    Goulden, Scott
    Sutcliffe, Frances
    Stevens, Andrew
    LANCET ONCOLOGY, 2012, 13 (02): : 127 - 128
  • [33] COMPARISON OF DASATINIB AND NILOTINIB AS SECOND-LINE THERAPY AFTER INATINIB FAILURE IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Tiribelli, M.
    Bonifacio, M.
    Binotto, G.
    Maino, E.
    Calistri, E.
    De Marchi, F.
    Scaffidi, L.
    Frison, L.
    Medeot, M.
    Ambrosetti, A.
    Semenzato, G.
    Fanin, R.
    HAEMATOLOGICA, 2015, 100 : 132 - 132
  • [34] Compassionate use of nilotinib (AMN107) in Mexican patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib
    Ayala, Manuel
    Hurtado, Rafael
    Nacho, Kevin
    Tapia, Norma
    Alvarado, Martha
    Aguayo, Alvaro
    Cleto, Sergio
    Lugo, Yolanda
    Reyes, Gustavo
    Vargas, Pablo
    Herrera, Angel
    Meillon, Luis Antonio
    BLOOD, 2007, 110 (11) : 216B - 216B
  • [35] Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure
    Quintas-Cardama, Alfonso
    Kantarjian, Hagop
    O'Brien, Susan
    Borthakur, Gautham
    Bruzzi, John
    Munden, Reginald
    Cortes, Jorge
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (25) : 3908 - 3914
  • [36] Dynamics and Management of Cytopenias Associated With Dasatinib Therapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Imatinib Failure
    Quintas-Cardama, Alfonso
    Santos, Fabio Pires De Souza
    Kantarjian, Hagop
    O'Brien, Susan
    Faderl, Stefan
    Awais, Ahmed
    Borthakur, Gautam
    Cortes, Jorge
    CANCER, 2009, 115 (17) : 3935 - 3943
  • [37] ECONOMIC EVALUATION OF DASATINIB IN CHRONIC MYELOGENOUS LEUKAEMIA PATIENTS RESISTANT TO IMATINIB IN PERU, COMPARED TO NILOTINIB AND HIGH DOSES OF IMATINIB
    Orozco Giraldo, J. J.
    Valencia, J. E.
    Garrido Lecca, S.
    Aiello, E. C.
    VALUE IN HEALTH, 2011, 14 (03) : A168 - A168
  • [38] Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure
    Palandri, Francesca
    Castagnetti, Fausto
    Soverini, Simona
    Poerio, Angela
    Gugliotta, Gabriele
    Luatti, Simona
    Amabile, Marilina
    Martinelli, Giovanni
    Rosti, Gianantonio
    Baccarani, Michele
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (12): : 1758 - 1761
  • [39] Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy
    Breccia, Massimo
    Cannella, Laura
    Nanni, Mauro
    Stefanizzi, Caterina
    Alimena, Giuliana
    ACTA HAEMATOLOGICA, 2007, 118 (03) : 162 - 164
  • [40] Experience with the Use of Nilotinib in Indian Patients
    Avaronnan Manuprasad
    Prasanth Ganesan
    Trivadi S. Ganesan
    Venkatraman Radhakrishnan
    Manikandan Dhanushkodi
    Samson Mani
    Tenali Gnana Sagar
    Indian Journal of Hematology and Blood Transfusion, 2018, 34 : 443 - 447
12345